We found that casticin could represent a novel and broadly applicable PI3K inhibitor that can be used for treatment against nasopharyngeal carcinoma cells and that casticin may provide potential clinical benefits for patients afflicted with nasopharyngeal carcinoma. This evidence concerns the gene PIK3CA and nasopharyngeal carcinoma.